Thomas Higgins - NeuroMetrix CFO
| NURO Stock | USD 4.25 0.10 2.41% |
CFO
Mr. Thomas T. Higgins is a Chief Financial Officer, Senior Vice President and Treasurer of NeuroMetrix Inc since 2009. Mr. Higgins was Executive Vice President and Chief Financial Officer at Caliper Life Sciences, Inc., a provider of technology and services for life sciences research. Before Caliper, Mr. Higgins was Executive Vice President, Operations and Chief Financial Officer at V.I. Technologies, Inc., a biotechnology company addressing blood safety. Before Vitex, Mr. Higgins served at Cabot Corporation in various senior finance and operations roles. His last position at Cabot was President of Distrigas of Massachusetts Corporationrationration, a subsidiary involved in the liquefied natural gas business, and prior to that he was Vice President and General Manager of Cabots Asia Pacific carbon black operations. Before joining Cabot, Mr. Higgins was with PricewaterhouseCoopers where he started his career since 2009.
| Age | 72 |
| Tenure | 15 years |
| Address | 4B Gill Street, Woburn, MA, United States, 01801 |
| Phone | 781 890 9989 |
| Web | https://www.neurometrix.com |
Thomas Higgins Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Higgins against NeuroMetrix stock is an integral part of due diligence when investing in NeuroMetrix. Thomas Higgins insider activity provides valuable insight into whether NeuroMetrix is net buyers or sellers over its current business cycle. Note, NeuroMetrix insiders must abide by specific rules, including filing SEC forms every time they buy or sell NeuroMetrix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Higgins 2 days ago Disposition of 498 shares by Thomas Higgins of NeuroMetrix at 3.03 subject to Rule 16b-3 | ||
Thomas Higgins over three months ago Acquisition by Thomas Higgins of 5625 shares of NeuroMetrix at 3.6 subject to Rule 16b-3 |
NeuroMetrix Management Efficiency
The company has return on total asset (ROA) of (0.2821) % which means that it has lost $0.2821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4278) %, meaning that it created substantial loss on money invested by shareholders. NeuroMetrix's management efficiency ratios could be used to measure how well NeuroMetrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to drop to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, NeuroMetrix's Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of November 2024, Other Current Assets is likely to grow to about 1.5 M, while Total Assets are likely to drop about 17.5 M.Similar Executives
| Found 1 records | CFO Age | ||
| Frances Scally | Bluejay Diagnostics | 57 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 |
NeuroMetrix Management Team
Elected by the shareholders, the NeuroMetrix's board of directors comprises two types of representatives: NeuroMetrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroMetrix. The board's role is to monitor NeuroMetrix's management team and ensure that shareholders' interests are well served. NeuroMetrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroMetrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xuan Kong, Chief Scientist | ||
| Thomas Higgins, CFO, Principal Accounting Officer, Sr. VP and Treasurer | ||
| Susan RN, Senior Care |
NeuroMetrix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuroMetrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (2.04) % | ||||
| Operating Margin | (2.97) % | ||||
| Current Valuation | (6.21 M) | ||||
| Shares Outstanding | 2.04 M | ||||
| Shares Owned By Insiders | 25.45 % | ||||
| Shares Owned By Institutions | 3.01 % | ||||
| Number Of Shares Shorted | 15.78 K | ||||
| Price To Earning | 6.51 X |
Pair Trading with NeuroMetrix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuroMetrix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuroMetrix will appreciate offsetting losses from the drop in the long position's value.Moving against NeuroMetrix Stock
The ability to find closely correlated positions to NeuroMetrix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuroMetrix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuroMetrix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuroMetrix to buy it.
The correlation of NeuroMetrix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuroMetrix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuroMetrix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuroMetrix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.62) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.